Please assess the completion status of the following clinical trial:

Trial Title: Needle-Free Injections of Gonadotropins for Superovulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing their first cycle of superovulation~* Age 18-39~* BMI 18-35 kg/m2~* Uterine cavity evaluation (hysterosalpingogram, sonohysterogram, hysteroscopy) normal in the preceding 6 or 12 months~* Early follicular phase (Day 2 or Day 3) serum FSH \<12 IU/L in the preceding 12 months~* Subject able to give informed consent~* At least 1 patent fallopian tube~* One semen analysis in the prior 12 months with total motile count \> 10M~Exclusion Criteria:~* Prior enrollment in this study~* Any prior early follicular phase serum FSH level ≥12 IU/L~* Previous ovarian stimulation with gonadotropins~* Diabetes mellitus or uncontrolled thyroid disease~* Abnormal uterine cavity, such as unresected submucosal fibroids, uterine septum, Mullerian anomaly such as bicornuate or unicornuate uterus or intrauterine adhesions~* Hydrosalpinx

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Needle free system (Type: EXPERIMENTAL): Intervention will consist of the gonadotropin BRAVELLE being injected using the Comfort-in™ needle free system for the duration of a standard superovulation cycle
- Standard needle injection system (Type: ACTIVE_COMPARATOR): Control patients will undergo their superovulation cycle using the gold standard subcutaneous needle injection system for their gonadotropin injections

Based on this trial design, predict the completion outcome and termination type (if applicable).